Tenet Healthcare Corporation
$ 183.69
-5.71%
14 Jul - close price
- Market Cap 15,822,506,000 USD
- Current Price $ 183.69
- High / Low $ 189.15 / 179.91
- Stock P/E 9.55
- Book Value 55.90
- EPS 19.23
- Next Earning Report 2026-07-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.30 %
- 52 Week High 247.21
- 52 Week Low 146.60
About
Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.
Analyst Target Price
$243.48
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-11 | 2025-10-28 | 2025-07-22 | 2025-04-29 | 2025-02-12 | 2024-10-29 | 2024-07-24 | 2024-04-30 | 2024-02-08 | 2023-10-30 | 2023-07-31 |
| Reported EPS | 4.82 | 4.7 | 3.7 | 4.02 | 4.36 | 3.44 | 2.93 | 2.31 | 3.22 | 2.68 | 1.44 | 1.44 |
| Estimated EPS | 4.17 | 4.07 | 3.35 | 2.87 | 3.13 | 2.8324 | 2.37 | 1.91 | 1.44 | 1.62 | 1.2 | 1.25 |
| Surprise | 0.65 | 0.63 | 0.35 | 1.15 | 1.23 | 0.6076 | 0.56 | 0.4 | 1.78 | 1.06 | 0.24 | 0.19 |
| Surprise Percentage | 15.5875% | 15.4791% | 10.4478% | 40.0697% | 39.2971% | 21.4518% | 23.6287% | 20.9424% | 123.6111% | 65.4321% | 20% | 15.2% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-24 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 4.08 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.01 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: THC
2026-07-14 20:13:42
Tenet Healthcare (THC) shares plunged 7% following a sector-wide sell-off triggered by HCA Healthcare cutting its full-year 2026 profit forecast. HCA attributed the cut to a shift in "payer mix" towards more uninsured patients, raising investor concerns about the financial impact of ACA turmoil on other hospital operators like Tenet. Despite this, Tenet had recently received positive news including a reiterated "Overweight" rating from Cantor Fitzgerald, strong Q1 2026 earnings, and a credit rating upgrade from Moody's.
2026-07-14 15:13:42
Tenet Healthcare Corporation experienced a 6.2% drop in its stock price despite Wells Fargo and Barclays maintaining "Overweight" ratings and increasing their price targets. The sell-off, despite positive analyst sentiment, suggests potential profit-taking or broader sector pressure. Investors are advised to watch for further company commentary and sector performance to determine if this dip is a buying opportunity or a signal of unacknowledged market concerns.
2026-07-14 01:12:40
Tenet Healthcare Corp (THC) shares have dropped 4.6% to $194.81, but are still considered 18.2% overvalued according to GuruFocus's GF Value™, which estimates a fair value of $164.77. The company holds a GF Score™ of 77/100, indicating above-average performance, primarily driven by strong profitability but tempered by weaker financial strength. Insider selling of $1.5 million over the past three months, with no corresponding buying, suggests a lack of confidence among executives regarding the company's immediate prospects or valuation.
2026-07-13 13:10:28
Wells Fargo has maintained an 'Overweight' rating for Tenet Healthcare (THC), increasing its price target from $213.00 to $231.00. While analysts have a positive outlook, GuruFocus indicates the stock is currently 24.0% overvalued with a GF Value™ of $164.77 versus its current price of $204.25. Insider activity shows $1.5 million in sales over the last three months with no reported purchases.
2026-07-11 23:10:28
This article provides the transcript for Tenet Healthcare's (THC) Q1 2026 earnings call. The transcript is powered by Quartr and details the financial discussion from the company's first quarter.
2026-07-10 22:10:08
Tenet Healthcare (THC) stock dipped 1.22% while the broader market gained, although it had previously outperformed its sector and the S&P 500. Investors are anticipating its upcoming earnings report on July 24, 2026, with projected EPS and revenue increases. The company holds a Zacks Rank #2 (Buy) and its valuation metrics are in line with its industry average.
